Update on Eckert & Ziegler€¦ · Investor Relations & PR Robert-Rössle-Str. 10 13125 Berlin Tel. +49 30 94 10 84-138 Fax +49 30 94 10 84-112 [email protected] 28.03.2013 Annual

1 Frankfurt 13.11.2012, Confidential

Update on Eckert & Ziegler

Eigenkapitalforum Frankfurt,

13. November 2012

Dr. Andreas Eckert, CEO


German High-Tech Built Around

Isotope Applications

Covering 4 Topics

Environmental

Services

Nuclear-pharmacy

and Radiopharmaceuticals

Radiation Therapy

(tumour Treatment)

Radioactive Components

for Measurement and Control


Grouped in 4 Segments with

116 mm€ Revenues 2011

Disposal

(ENVIRONMENTAL

SERVICES)

Nuclear

Medicine

(RADIOPHARMA)

Industrial Components

(ISOTOPE

PRODUCTS)

Medical Devices for

Radiation (RADIATION THERAPY)

Prostate Implants

Eye Applicators

Devices for Radiation of

Cancer (Afterloader)

Accessories

Industrial Components

Medical Imaging

Calibration Sources

Radioisotopes

Synthesis Modules

Radio-Diagnostics

(mainly FDG)

Generators

Pharmaceutical

Yttrium 90

Source Retraction

Disposal

54,6 mm€

47%

30,4 mm€

26%

25,6 mm€

22%

5,5 mm€

5%


Today 610 Employees

in 17 Locations Worldwide

+ dense network

of specialised

distribution partners

HQ: Berlin

USA: 150 employees Germany: 410 employees

EU / ROW:

50 employees


Revenue Growth Since

Foundation in 1992

0,13 1 2 4 6 6 8 10

24

33 31 29

3642

5054

71

101

111116 117

125

0

20

40

60

80

100

120

140

1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012e 2013g

Consolidated Revenues in mm€

5


Long-Term Development of

EBIT

EBIT in mm€

(Recurring EBIT before 2009 – including elimination of one-offs)

6 Slides only for illustration – the spoken word shall be binding

1,12,2

3,9 4,35,5 5,7

6,9

14,6

16,6

22,9

18,9

21,4

2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012e 2013g


Due to Lower Tax: Net Income

2012 = 2011; Increase in 2013

3,4

7,5

9,410,4 10,3

12,2

0

2

4

6

8

10

12

14

0,00

0,50

1,00

1,50

2,00

2,50

2008 2009 2010 2011 2012e 2013g

Net Profit/ Share Net Profit mm€


Growth drivers 2013

-2,5

-0,5

1,5

3,5

5,5

7,5

9,5

11,5

-20

0

20

40

60

80

100

Isotope Products Radiation Therapy Radiopharma Environmental Sevices

Revenues 2012 Revenues 2013 Net Income 2012 Net Income 2013

Net Income

in mm€ Revenues

in mm€

Isotope Products Radiation Therapy RadiopharmaEnvironmental

Sevices

Revenue growth + 4 + 1 + 2 + 1

Net income growth + 0,8 + 0,5 - 0,1 + 0,5

Reasons Economies of scale

Increasing revenues

and profits from

cancer radiation

devices

Regional expansion

in Poland

Lower losses from

waste provision

adjustments


Cashflow

Operational CF

Investments

7 9

2215

20 18

-5 -5 -10 -8 -9 -7

24

-22

-8-7

-30

-20

-10

0

10

20

30

40

50

2007 2008 2009 2010 2011 2012e

Financing

Capital increase

9


Healthy Balance Sheet

Cash 34 Equity 80

Receivables 21 Minorities 6

Inventory 15 Debt 15

Intang. asstes 46 Accruals 27

Tang. assets 29 Other short-term liab. 26

Other 13 Other long-term liab. 4

Assets 158 Equity & Liabilities 158

Debt redemption < 1 year

Equity ratio > 50%

in mm€


Increase of Net-Cash 2012e

to 22 mm€

-8-11

24

7

14

22

-20

-10

0

10

20

30

40

50

2007 2008 2009 2010 2011 2012e

Debt Cash Net Cash

in mm€

11


Key Parameter 2008 to 2013e

7

1517

23

1921

-11

7

1471

101

111116 115

127

0

20

40

60

80

100

120

140

-15

-10

-5

0

5

10

15

20

25

30

2008 2009 2010 2011 2012e 2013g

EBIT Net Cash Revenues


Various Topics


Eckert & Ziegler Vitalea Science Inc.

San Francisco

Acquired in Q3 2012


Vitalea Science

Industry Leaders

• 2003 Founders : Stephen Dueker, Le Vuong,

John Vogel

• Innovators of next generation BioMICADAS

AMS technology

• Founders of applied AMS methods for

biological determinations

CRO Industry Experience (GLP Facility)

• Strong commitment to quality and regulated bioanalysis

• Highly skilled solutions oriented scientific

team

Meeting Aggressive Timelines

• Understanding the critical nature of the industry

3. Filter

molecule destruction

3. Filter


2. Filter

mass analysis

(low-energy end)

2. Filter

mass analysis

(low-energy end)

mass

spectrometer

charge exchange

5. Filter

particle identification

5. Filter


4. Filter

mass analysis

(high-energy end)

4. Filter

mass analysis

(high-energy end)

mass

spectrometer

electrostatic

deflector

1.Filter

negative ion formation

1.Filter


13C / 12C14C / 12C

(Stripping process)

13CH-

12CH2-

14C-

argon stripper gasnegative ions positive ions

14C+

13C+

12C+

H+

10-9

1

1

:

:

7Li2-

12C

13C

3. Filter


3. Filter


2. Filter

mass analysis

(low-energy end)

2. Filter

mass analysis

(low-energy end)

mass

spectrometer

charge exchange

5. Filter


5. Filter


4. Filter

mass analysis

(high-energy end)

4. Filter

mass analysis

(high-energy end)

mass

spectrometer

electrostatic

deflector

1.Filter


1.Filter


13C / 12C14C / 12C

(Stripping process)

13CH-

12CH2-

14C-

argon stripper gasnegative ions positive ions

14C+

13C+

12C+

H+

10-9

1

1

:

:

7Li2-

12C

13C

Bioanalytical Contract Research Organization: Addressing Unmet Needs with

Accelerator Mass Spectrometry (AMS)


Vitalea Science

Pharmaceutical: New Drug Development

Ultra- low level (14C) analysis for Microdosing and Microtracing

studies – exploring new drugs in humans

In-vivo lead optimization under exploratory IND

Advance pediatric research in intended population

Safety testing in early human development vs. animal

Medical diagnostics: predicting patient response to new cancer

treatments

Biobased Content

Biofuels process monitoring and authentication for labeling

percent modern carbon

Biocontent of manufactured products authentication and forensic

counterfeit investigations

Carbon Dating

Archeology - authentication


Future Expansion Parameters

• Synergistic / Additive to existing businesses

• ‘Good Radiation’

• European or International is better than US

• Valuation Expectations are lower

• Distressed Division of Multinational

• 20 - 50 mm€ is target

• 10 mm€ is to small


Alzheimer´s Disease as PET

Market Growth Driver

• Amyloid PET imaging agents to enter G-8 markets within

2013 and 2014

– Amyvid (AVID/ Eli Lilly)

– Flutemetamol (GE)

– Florbetaben (Piramal)

• Disease modifying therapies to enter in 2013ff; will expand

diagnostic market

– Solanezumab (Eli Lilly)

– Gammagard (Baxter)


Backup


Low Radioactive Implants

against Prostate Cancer

Brachytherapy with implants:

• effectiv

• low side effects

• cost efficient

• production site in Berlin


Tumor Radiation Device

Multisource® with Co-60-source

Main advantage against competing products

• low operating costs

• robust design

• new treatment planning program


Brachytherapy Sources

for Special Use

Ruthenium-106

Eye-applicators

Eckert & Ziegler BEBIG GmbH

(therapy segment )


Fluor-18 Contrast Media

for Cancer Diagnostic

Tumour well identifiable

F-18-Fluordesoxyglukose (FDG)

from our Berlin Zyklotron production


Production Devices

for Nuclear Medicine

Modular-Lab

Fully automated

flexible to

configurable

Synthesis modules

for produce short

life radioactive

materials


Radioembolization

Produktdetails siehe u.a. www.sirtex.com

Radioembolization is a new treatment option

for loco-regional treatment of primary and

secondary liver tumors.

SIRT is based on the delivery of radioactive

labeled microspheres into the vascular bed

of the liver via angiographically placed

catheters in the branches of the hepatic

artery.

http://www.sirtex.com/


Contract Labelling

of Radio-Immunotherapeutics

ZEVALIN:

• FDA approved for

Non-Hodgking Lymphoma

• 5-Year Survival Rate > 54%

• 43.000 patients per year

•Further indications under

development


Innovative Isotope Products

for Ophthalmic Diseases

Epi-Rad90TM

radiation system

Treatment of age-related

macular degeneration

Objective: patient friendly and cost-efficient radiation of the choroidal neovascularization

Vorgestellt u.a. DGMP

Oldenburg 2008,

Zur Zeit in klinischen

Prüfungen der Phase III


Low Level Radioacitve

Waste Management Services

Collection of waste

Konrad-

conditioning

Intermediate products Row waste

Final repository

waste

conditioning

Transportation Konrad-Container,

Temporary storage Intermediate storage

Facility Leese


Final Product: Indestructible

Concrete Decay Container

• conditioning with process plan

• process plan for producing special containers

• process plan for pouring Konrad containers

revenue per

container

up to

120.000 EUR


Quality Assurance for

Nuclear Medical Imaging

Ge-68 radiation sources

in gamma cameras


Measuring Technique for

Industry and Science

Products for Nuclear Imaging and Industry:

Reference and calibration sources for medical applications

Sealed sources for measurement systems

Calibration sources for scientific applications

Radioisotopes


Components for Industrial

Quality Assurance


Summary

• solid financials

• dividend paying stock

• leading market position

• 4 segments relatively independent / diversified business

• high market entry barriers for new players

• less cyclical than other industry sectors

• driven by the demographic development & medical progress

• Management has long-term focus being the largest shareholder

• undervalued (P/E ratio 11)


Shareholder Structure &

Share details

Shareholder Structure as of November 2012

Share details

32,1%

0,1%67,8%

Management

Eckert & Ziegler AG

Freefloat

IPO May 1999

Number of shares 5.292.983

Share price (8/11/2012) 23,07 €

Market capitalization 120,7 mm€


Analyst Coverage

DZ Bank

Dr. Christa Bähr

Phone: +49 69 7447 7242

Hauck & Aufhäuser

Torben Teichler

Phone: +49 40 41 43 885 74


ISIN DE0005659700

Reuters EUZ.DE

Financial Calendar / IR-Contact

IR-Contact

Eckert & Ziegler AG

Karolin Riehle

Investor Relations & PR

Robert-Rössle-Str. 10

13125 Berlin

Tel. +49 30 94 10 84-138

Fax +49 30 94 10 84-112

[email protected]

www.ezag.de

28.03.2013 Annual Report 2012

28.03.2013 Balance Press Conference in Berlin

May 2013 Entry and General Standard Conference

in Frankfurt

03.05.2013 Quarterly Report I/2013

17.05.2013 Annual Shareholder Meeting

15.08.2013 Quarterly Report II/2013

08.11.2013 Quarterly Report III/2013

Documents

Update on Eckert & Ziegler€¦ · Investor Relations & PR Robert-Rössle-Str. 10 13125 Berlin Tel. +49 30 94 10 84-138 Fax +49 30 94 10 84-112 [email protected] 28.03.2013 Annual